VNDA · Vanda Pharmaceuticals Inc.

The resignation of Timothy Williams from the triple-hatted role of Senior Vice President, General Counsel and Secretary represents a material leadership change for Vanda Pharmaceuticals Inc. This position carries responsibility for legal oversight, SEC compliance, corporate governance, board support, and regulatory strategy — functions critical to a biopharmaceutical company operating in a highly scrutinized environment. His departure, effective April 10, 2026, follows formal notification on March 29, 2026, allowing for a brief but defined transition period. The absence of any disclosed dispute, regulatory issue, or financial reporting concern in the filing suggests an amicable and voluntary exit. However, the timing and lack of announced successor may introduce near-term operational and governance execution risk, particularly if the company is engaged in active litigation, regulatory submissions, or capital markets activity. Investors will monitor for disclosures regarding interim coverage, search timeline, and whether the role will be restructured or split post-transition.